Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts
Cancer Medicine · 2023
DOI: 10.1002/cam4.6819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Suzanne Fastner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Utah, Department of Dermatology, Huntsman Cancer Foundation, U.S. Department of Defense.
Abstract (Originalsprache)
Objectives
To investigate current practices and attitudes regarding use of adjuvant immunotherapy and prognostic gene expression profile (GEP) testing among melanoma medical and surgical oncologists.
Methods
An anonymous RedCap‐based survey was emailed to ~300 melanoma experts.
Results
Respondents generally favored adjuvant immunotherapy over observation (73% for all Stage IIIA, 50% for Stage IIB/IIC) and cited a minimum 10‐year recurrence risk of 11%–20% (48%) or 21%–30% (33%) to justify treatment, but acknowledged that risks of serious adverse events may outweigh potential benefits for some Stage IIB/IIC patients. While GEP test results did not strongly influence decision‐making regarding follow‐up or intervention, most were receptive to randomized trials using GEP testing to identify subsets of Stage IIB/IIC (74%) and Stage IB/IIA (54%) patients who may not or may, respectively, benefit from adjuvant therapy.
Conclusion
Although most respondents do not routinely use GEP testing, many would participate in clinical trials to determine clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
- Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
- Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Dermatology, VA Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts, USA.
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, Tufts Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Douglas Grossman
Förderung
- University of Utah, Department of Dermatology
- Huntsman Cancer Foundation
- U.S. Department of Defense
- VA Integrated Service Network
- University of Utah
Zitieren
APA
Fastner, S., Shen, N., Hartman, R. I., Chu, E. Y., Kim, C. C., Kirkwood, J. M., & Grossman, D. (2023). Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Medicine. https://doi.org/10.1002/cam4.6819
Vancouver
Fastner S, Shen N, Hartman RI, Chu EY, Kim CC, Kirkwood JM, et al. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Medicine. 2023. doi:10.1002/cam4.6819
BibTeX
@article{Fastner2023,
author = {Fastner, Suzanne and Shen, Nathan and Hartman, Rebecca I and Chu, Emily Y and Kim, Caroline C and Kirkwood, John M and Grossman, Douglas},
title = {Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6819}
}
EUVIMED